Jim Tananbaum
Foresite Capital

Jim Tananbaum founded Foresite Capital in 2011 to merge his entrepreneurial experience and networks gained from 25 years in healthcare investing. Throughout his career, he has excelled at systematic and deep technical analysis of healthcare opportunities, while supporting the growth of companies from small enterprises into enduring franchises. Jim designed Foresite Capital to scale his previous experiences. Foresite Capital has grown into a full lifecycle investor with a foundation of technical excellence and a unique culture of internal and external collaboration. Jim’s goal is for Foresite Capital and each of its portfolio companies to deliver important novel products to address critical needs in our healthcare system.

Prior to founding Foresite Capital, Jim co-founded two leading biopharmaceutical companies and two healthcare investment practices. While finishing Harvard University Medical and Business Schools and earning an MS from the Massachusetts Institute of Technology (MIT), he founded GelTex Pharmaceuticals (NASDAQ:GENZ), which brought two drugs to market for less than $80 million. GelTex was acquired in 1998 for $1.6 billion, when its lead drug, Renagel (Renzela) had an annual revenue run rate in excess of $200 million. Today, Renzela is estimated to produce close to $1 billion in annual revenue, 22 years after its launch. Jimalso co-founded and was CEO of Theravance, Inc. which shares GSK’s respiratory franchise through a joint venture, Innoviva (NASDAQ: INVA), and completed a spin-off, Theravance Biopharma, Inc. (NASDAQ: TBPH). The two companies have a combined market capitalization of approximately $3.2 billion.

Jim’s investment experience includes being a founding partner of Prospect Venture Partners II and III, and earlier in his career, a partner at Sierra Ventures, where he helped establish its healthcare services investment practice. Jim has led numerous investments, including Amira Pharmaceuticals (acquired by NYSE: BMS), Amerigroup (NASDAQ: AMGP), Healtheon (NASDAQ:WBMD), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim founded Foresite Capital with the vision of marrying elements of all aspects of his career to create a novel investment platform.